Abstract
Intervertebral disc disease is a prevalent and costly clinical problem in the United States. Disease-modifying therapies applied at the early stages of disease are desirable compared to the traditional and variably effective surgical options for end-stage disease. A better understanding of the normal intervertebral disc and the molecular and cellular basis of disc degeneration has led researchers to investigate innovative therapies. Specifically the developments of biomaterial-based hydrogels and annular patches, cell implantation, growth factor modulation, and gene transduction techniques all hold clinical promise. The most powerful therapy may combine several of these modalities to achieve long-standing results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
